REAL-WORLD STUDY OF METASTATIC MERKEL CELL CARCINOMA PATIENTS RECEIVING CHECKPOINT INHIBITORS (CPIS) VS. CHEMOTHERAPY TREATMENTS

被引：0
|
作者：
Zheng, Y. [1 ]
Kim, R. [2 ]
Yu, T. [1 ]
Dreyfus, J. [3 ]
Gayle, J. A. [3 ]
Wassel, C. L. [3 ]
Phatak, H. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Premier Inc, Charlotte, NC USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.435
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN317
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [21] Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
    Bol, Kalijn Fredrike
    Ellebaek, Eva
    Hoejberg, Lise
    Bagger, Mette Marie
    Larsen, Mathilde Skaarup
    Klausen, Tobias Wirenfeldt
    Kohler, Ulrich Heide
    Schmidt, Henrik
    Bastholt, Lars
    Kiilgaard, Jens Folke
    Donia, Marco
    Svane, Inge Marie
    CANCERS, 2019, 11 (10)
  • [22] Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study
    Zhu, Jianfen
    Ding, Xiaokai
    Zhang, Jianna
    Chen, Bo
    You, Xiaohan
    Chen, Xinxin
    Chen, Tianxin
    BMC CANCER, 2024, 24 (01)
  • [23] Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapy
    Becker, J.
    Lorenz, E.
    Haas, G.
    Helwig, C.
    Oksen, D.
    Mahnke, L.
    Bharmal, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] REAL-WORLD OUTCOMES OF PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH SECOND-LINE OR LATER CHEMOTHERAPY IN A COMMUNITY ONCOLOGY SETTING IN THE UNITED STATES
    Cowey, C. L.
    Mahnke, L.
    Espirito, J.
    Fox, P.
    Helwig, C.
    Oksen, D.
    Bharmal, M.
    VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
  • [25] Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world evidence
    Hein, Erica C. Koch
    Vilbert, Maysa
    Hirsch, Ian
    Ribeiro, Mauricio Fernando
    Mantle, Luke
    Fournier, Cynthia
    Butler, Marcus O.
    Spreafico, Anna
    Saibil, Samuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS
    Cowey, C. L.
    Mahnke, L.
    Espirito, J.
    Helwig, C.
    Oksen, D.
    Bharmal, M.
    VALUE IN HEALTH, 2017, 20 (05) : A95 - A95
  • [27] The prognostic value of Meet-URO score in patients with metastatic clear cell renal cell carcinoma receiving second or third-line tyrosine kinase inhibitors/immune checkpoint inhibitors combination therapy: A real-world study
    He, Sike
    Liu, Haoyang
    Chen, Junru
    Sun, Guangxi
    Liu, Zhenhua
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
    Morgans, A. K.
    Divan, H. A.
    Birtle, A. J.
    Dorff, T.
    Ozatilgan, A.
    Graff, J. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 334 - 334
  • [29] Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma
    Voog, E
    Biron, P
    Martin, JP
    Blay, JY
    CANCER, 1999, 85 (12) : 2589 - 2595
  • [30] Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma
    Luke S. McLean
    Annette M. Lim
    Mathias Bressel
    Alesha A. Thai
    Danny Rischin
    Drugs & Aging, 2024, 41 : 271 - 281
12345